Job Description

POSITION SUMMARY:

The Gene Editing/Pharmacology Services Sales Manager will be responsible for gene-targeting, mouse model licensing/sales, and preclinical studies in the assigned territory; for meeting business goals/achieving territory Quota, and for developing new business opportunities and programs.

JOB RESPONSIBILITIES:

● Achieve corporate sales goals in the assigned territory

● Actively reach out to prospective customers, explore business opportunities, manage negotiations and secure contracts

● Clearly communicate gene targeting principles and preclinical services to potential customers

● Attend trade shows/relevant conferences

● Provide feedback to the company leadership regarding competitive offerings, prospect needs and product development ideas

● Support the Marketing Team in developing the Biocytogen brand and building awareness in the market place

REQUIRED SKILLS AND EXPERIENCE:

● Ph.D. in pharmacology or immunology or related field (3-5 years experience in a job-related field is preferred)

● Proven track record of revenue generation is a plus

● Strong interest in sales with motivation to learn advances in biotechnology

● Excellent written and oral communication skills

● Willingness to travel (i.e. customer meetings, conferences/vendor shows)

Company Description

Biocytogen was founded in 2009 and headquartered in Beijing, with three affiliates both in US and China. We are one of the global leaders in gene targeted animal model production, preclinical in vivo efficacy studies and pharmacological services. We have developed two excellent platforms: 1) custom gene targeting service platform, which features our innovative CRISPR-based Extreme Genome Editing (EGE®) technology. EGE® technology increases large fragment knockin efficiency by 10-20 fold for multiple gene editing models including cell lines, rats, mice and other species at low cost. Over 2,000 knockout/knockin mouse and rat models have been delivered worldwide, and this number is rapidly expanding. 2) Immuno-Oncology drug service platform, which is comprised of humanized immune checkpoint mouse models (e.g. B-hPD-1 mice) and immunodeficient animals with human immune system reconstruction (B-NDG mice). All models have been generated independently by Biocytogen. These models are very useful in in vivo efficacy studies to directly evaluate antibody and compound candidates targeting specific human immune checkpoints at various stages of your drug development. Biocytogen has established a global technical service network which relies on our unique technical platforms, standard operation procedures, strict quality control systems, talented scientists, and an efficient management team. The scientific team in our recently opened Boston branch are focusing on preclinical animal in vivo efficacy and pharmacology service to speed up your drug development.